国际医药卫生导报
國際醫藥衛生導報
국제의약위생도보
INTERNATIONAL MEDICINE & HEALTH GUIDANCE NEWS
2011年
18期
2297-2299
,共3页
李含秋%王西林%梁迎春%殷青云%郑洪波
李含鞦%王西林%樑迎春%慇青雲%鄭洪波
리함추%왕서림%량영춘%은청운%정홍파
新型抗精神病药%儿童分裂症
新型抗精神病藥%兒童分裂癥
신형항정신병약%인동분렬증
New antipsychotic drugs%Children schizophrenia
目的 比较新型抗精神病药(new generation atypical drug,NAD)奥氮平、利培酮、奎硫平在儿童分裂症中的应用。方法 共纳入使用奥氮平、利培酮及奎硫平的儿童分裂症患者66例,根据病历病情记录分别在治疗前及治疗第2、4、8周末采用临床疗效总评量表(CGI)评定临床疗效,用副反应量表(TESS)评定药物不良反应。结果 利培酮组有效率为71.0%,奥氮平组有效率为85.7%,奎硫平组有效率为60.0%,总有效率为72.7%;利培酮组的副反应发生率为21.0%,奥氮平组的副反应发生率为33.0%,奎硫平组的副反应发生率为30.0%。结论 NAD对儿童分裂症安全有效,NAD已较为广泛地应用于儿童精神分裂症。
目的 比較新型抗精神病藥(new generation atypical drug,NAD)奧氮平、利培酮、奎硫平在兒童分裂癥中的應用。方法 共納入使用奧氮平、利培酮及奎硫平的兒童分裂癥患者66例,根據病歷病情記錄分彆在治療前及治療第2、4、8週末採用臨床療效總評量錶(CGI)評定臨床療效,用副反應量錶(TESS)評定藥物不良反應。結果 利培酮組有效率為71.0%,奧氮平組有效率為85.7%,奎硫平組有效率為60.0%,總有效率為72.7%;利培酮組的副反應髮生率為21.0%,奧氮平組的副反應髮生率為33.0%,奎硫平組的副反應髮生率為30.0%。結論 NAD對兒童分裂癥安全有效,NAD已較為廣汎地應用于兒童精神分裂癥。
목적 비교신형항정신병약(new generation atypical drug,NAD)오담평、리배동、규류평재인동분렬증중적응용。방법 공납입사용오담평、리배동급규류평적인동분렬증환자66례,근거병력병정기록분별재치료전급치료제2、4、8주말채용림상료효총평량표(CGI)평정림상료효,용부반응량표(TESS)평정약물불량반응。결과 리배동조유효솔위71.0%,오담평조유효솔위85.7%,규류평조유효솔위60.0%,총유효솔위72.7%;리배동조적부반응발생솔위21.0%,오담평조적부반응발생솔위33.0%,규류평조적부반응발생솔위30.0%。결론 NAD대인동분렬증안전유효,NAD이교위엄범지응용우인동정신분렬증。
Objective To compare the use of new antipsychotic drugs (NAD) including Olanzapine, Risperidone and Qutipine in the treatment for children with schizophrenia. Methods 66 children patients were included in this study, according to the case disease condition history, we evaluated the efficacy and side effects with CGI and TESS before treatment, and at the 2nd,4th ,8th weeks after the treatment. Results The response rate of Risperidone, Olazapine and Qutipine are 71%, 85.7%, and 60% respectively. The total response rate is 72.7%. The rates of side effects are 21%, 33%, 30%respectively. Conclusion It suggested that NAD is effective and safe in the treatment for children schizophrenia patients. NAD has been widely used in children schizophrenia outpatients.